Redeye updates its estimates for the Q2 report, with slightly lower sales but a higher operating mar...
Q2 report due on 11 August We cut ‘22e-‘24e EBIT by 17%, 5%, and 4% 14% FCF yield with positive grow...
Our analyst summarizes the investment case: “Eevia Health offer organic plant extracts for food nutr...
Analyst Group inleder idag den 29:e juni 2022 bevakning på EcoRub, vilket innefattar kontinuerlig an...
Redeye leaves a comment following Faron Pharmaceutical’s announcement earlier today of a placing of ...
Q2 report due Tuesday, 26 July We expect positive sales growth to continue… …but margins to still be...
On June 22, 2022, Fluicell announced that they have been selected as one out of ten most innovative ...
Redeye is encouraged to learn that 2cureX has signed its 10th distribution agreement.
Redeye makes an adjustment to the project’s LOA based on results from BT-001’s phase I trial, part A...
Katalysen Ventures är en venture developer med kontor i Sverige, Schweiz och USA.
Redeye comments on the news regarding ISAB's latest IRS order worth SEK 518,000.
Kommentar på finansiella siffror Diamyd rapporterade under morgonen sin rapport för det tredje kvart...
We trim our growth assumptions Slower rental growth hedges against price fall 11x ’23e P/IFPM and 5...
Redo för att accelerera sin förvärvsresa... Bergman & Beving (B&B) förvärvar och utvecklar ledande f...
Bolaget genomförde en riktad emission i syfte att stärka ägarsidan vilket påverkade resultatet för Q...
Redeye views the news that SaveLend Group signs an agreement for a new institutional investor to joi...
Redeye is encouraged to learn that Devyser has been awarded a tender from Héma-Québec in Québec, Can...
Redeye provides a comment on Cantargia’s recently announced rights issue.
Redeye comments on Evolution’s acquisition of Nolimit City which is a small acquisition that expands...
AlzeCure Pharma meddelade igår att den första patienten har inkluderats i en klinisk fas 2-studie me...
